Stoke Therapeutics Inc. (STOK) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 14.79 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
SEC XBRL FY 2025 (10-K): 24.4% FCF Margin ($44.9M FCF) & 52% Gross Margin
Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment
Even with a 59/100 (C-) score, STOK faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (+0.16% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.43) or 200D SMA ($30.92) invalidates the momentum regime and cuts Target Base ($26.47) toward Bear Floor ($20.65).
Stoke Therapeutics Inc. (STOK) slipped -0.23% to $26.35, trading at 30% of its 52-week range ($20.32 – $40.22). Solid steady margins (-6% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Stoke Therapeutics slipped 0.2% to US$26.29 after posting Q3 2026 numbers, a muted reaction for a biotech still deep in the development stage. On the surface, the latest quarter showed revenue of US$11.3 million alongsid
Dravet syndrome trial enrollment exceeded targets with zero discontinuations.
Moby summary of Stoke Therapeutics, Inc.'s Q3 2026 earnings call
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulato
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsThomas Leggett - Chief Financial OfficerIan Smith -...
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
BEDFORD, Mass., October 29, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investiga
Stoke Therapeutics (NASDAQ:STOK) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.13 percent. This is a 66.15 percent decrease over losses of $(0.65) per share
Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs, market share of individual therapies, and current and forecasted market s
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on STOK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for STOK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Stoke Therapeutics Inc. (STOK) ranks #213 by composite RQD confidence (59/100, grade C-) and #287 by equity capitalization ($1.70B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with STOK at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STOK
ACTIVE
Stoke Therapeutics Inc. | C- | 59/100 | — | — | -6.1% | -0.23% | $1.70B | Benchmark Subject |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-stok → |
| NBTX Nanobiotix S.A. | D+ | 52/100 | — | — | — | -0.53% | $1.72B | /nbtx-vs-stok → |
| ANIP ANI Pharmaceuticals Inc. | B- | 70/100 | 21.5x | — | 16.0% | +2.02% | $1.68B | /anip-vs-stok → |
| NUVB Nuvation Bio Inc. (Class A) | E | 29/100 | — | — | -35.0% | +3.92% | $1.67B | /nuvb-vs-stok → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stoke Therapeutics Inc. (STOK) reported GAAP revenue of $184.4M (+404.5% vs. FY2024 revenue of $36.6M , and +2000.5% cumulative change since FY2023) , GAAP net income of -$6.9M, operating cash flow of $45.6M, and free cash flow of $44.9M (+151.6% YoY). On the balance sheet, STOK closed FY2025 with $418.4M in total assets against $0 in total debt (Altman Z-Score: 14.79, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $184.4M | -$6.9M | $45.6M | $44.9M | $418.4M | — |
| FY2024 (FY) | 2024-12-31 | $36.6M | -$89.0M | -$86.9M | -$87.1M | $271.6M | — |
| FY2023 (FY) | 2023-12-31 | $8.8M | -$104.7M | -$81.1M | -$81.1M | — | — |
As of 2026-11-01, Stoke Therapeutics Inc. (NASDAQ: STOK) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $26.35 (-0.23% 1D, market cap $1.70B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, STOK ranks #213 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STOK carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.1%. By comparison, CMPS (COMPASS Pathways Plc American Depository Shares) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B) and NBTX (Nanobiotix S.A.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.72B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
Per STOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001623526), Stoke Therapeutics Inc. generated $184.4M in revenue (+404.5% YoY), -$6.9M in net income, and $44.9M in free cash flow against $418.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
STOK last traded at $26.35 (-0.23% on volume of 1,879,654 shares), positioning the stock -3.94% below its 50-day simple moving average ($27.43) and -14.78% below its 200-day simple moving average ($30.92). Across its 52-week range of $20.32 to $40.22, STOK sits at the 30.3% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($23.43 to $29.27).
Why STOK Stock slipped -0.23% Today — RQD Quant Desk Flash. Solid steady margins (-6% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.